I’ve just come back from the World Evidence, Pricing and Access (EPA) Congress at the RAI Congress Centre in Amsterdam.
I’m sure you know it – one of the world’s largest pharma events, where over 300 speakers compete for the attention of over 1,500 delegates and eight workstreams.
Interesting to see what these workstreams were, as it gives you a flavour of what we, as an industry, think will be important over the next year and beyond.
They broke down as – market access (in the main plenary), health economics and outcomes research (always well attended), pricing (as expected, busy), health technology assessment (ditto), evidence, advanced therapies, rare diseases and digital transformation (right at the end of the furthest corridor, difficult to find and often playing sessions that had, frankly, nothing to do with digital transformation).
Check out the rest of the feature here
